In spite of dramatic improvements in cure rate for the most common childhood malignancy, acute lymphoblastic leukemia (ALL), one in four to five children will suffer disease reoccurrence and their prognosis is dismal. In fact relapsed ALL is the most common cause of non-accidental death in childhood. Attempts to improve relapse outcome by intensifying chemotherapy including the use of stem cell transplantation have failed to cure the majority of children. While many prognostic factors can be used to stratify therapy, only immunophenotype (T-ALL inferior prognosis), site of relapse (bone marrow inferior to isolated extramedullary) and timing of relapse (early relapse defined as <36 months from initial diagnosis inferior compared to late relapse) are predictive of salvage. To discover the underlying pathways that mediate drug resistance in childhood ALL we have used high throughput genomic techniques to analyze differences in global gene expression and copy number abnormalities (CNAs) in matched diagnosis-relapse paired samples from children enrolled on Children's Oncology Group (COG) protocols. Our early results indicate that most cases of early relapse are characterized by a proliferative gene signature and we suggest that these clones exist at diagnosis. In contrast, we hypothesize that many cases of late relapse occur through acquisition of additional genetic and/or epigenetic changes. Importantly, we have identified attractive targets for novel therapeutic approaches including a subset that have been validated in preclinical assays. The goals of this application are to extend these observations and confirm our hypothesis through the following specific aims: 1) discover biological pathways responsible for the emergence of resistant disease by identifying gene signatures associated with early and late relapse using oligonucleotide arrays, 2) to determine the critical lesions that drive resistance by identifying CNAs unique to the relapsed clone using Affymetrix 6.0 SNP arrays, 3) to validate the critical roles of the pathways identified in aims 1 and 2 by modulating expression in a panel of ALL cell lines exposed to chemotherapy and to establish whether transcript levels correlate with the drug sensitivity of blasts exposed ex vivo to agents used in ALL treatment, and 4) to formally test our hypothesis by documenting the evolution of gene expression signatures in residual blasts at end induction, and by "backtracking" relapse specific deletions to determine if relapsed clones were present at diagnosis before the application of therapy. The results of these studies will lead to an understanding of the cellular origin of relapsed disease and the pathways that are responsible for treatment failure. Such information will lead to the discovery of pathways that can be targeted in future trials.
Although the majority of children who are newly diagnosed with acute lymphoblastic leukemia (ALL) are now cured, recurrences develop, often unpredictably, in 25% of cases. Success in treating relapse has significantly lagged behind that of newly diagnosed disease as evidenced by the fact that only approximately one third of children with recurrent ALL survive long-term. The goal of this project is to develop a better understanding of the molecular genetic events that lead to relapse so that this knowledge can be used to identify more effective preventative and therapeutic strategies.
|Bhatla, Teena; Jones, Courtney L; Meyer, Julia A et al. (2014) The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol 36:413-8|
|Chatterton, Zac; Morenos, Leah; Mechinaud, Francoise et al. (2014) Epigenetic deregulation in pediatric acute lymphoblastic leukemia. Epigenetics 9:459-67|
|Dandekar, Smita; Romanos-Sirakis, Eleny; Pais, Faye et al. (2014) Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol 167:87-99|
|Raetz, Elizabeth A; Morrison, Debra; Romanos-Sirakis, Eleny et al. (2014) A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leu J Pediatr Hematol Oncol 36:458-63|
|Vitanza, Nicholas A; Zaky, Wafik; Blum, Roy et al. (2014) Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 61:1779-85|
|Jones, Courtney L; Bhatla, Teena; Blum, Roy et al. (2014) Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem 289:20502-15|
|Meyer, Julia A; Wang, Jinhua; Hogan, Laura E et al. (2013) Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45:290-4|
|Bhatla, Teena; Wang, Jinhua; Morrison, Debra J et al. (2012) Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119:5201-10|
|Morrison, D J; Hogan, L E; Condos, G et al. (2012) Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 26:271-9|
|Hogan, Laura E; Meyer, Julia A; Yang, Jun et al. (2011) Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 118:5218-26|